[EN] USE OF CYCLIC ANABAENOPEPTIN-TYPE PEPTIDES FOR THE TREATMENT OF A CONDITION WHEREIN INHIBITION OF CARBOXYPEPTIDASE U IS BENEFICIAL, NOVEL ANABAENOPEPTIN DERIVATIVES AND INTERMEDIATES THEREOF [FR] UTILISATION DE PEPTIDES CYCLIQUES DE TYPE ANABAENOPEPTINE DESTINES AU TRAITEMENT D'UN ETAT POUR LEQUEL L'INHIBITION DE LA CARBOXYPEPTIDASE U EST BENEFIQUE, DERIVES DE L'ANABAENOPEPTINE ET INTERMEDIAIRES DE CELLE-CI
[EN] USE OF CYCLIC ANABAENOPEPTIN-TYPE PEPTIDES FOR THE TREATMENT OF A CONDITION WHEREIN INHIBITION OF CARBOXYPEPTIDASE U IS BENEFICIAL, NOVEL ANABAENOPEPTIN DERIVATIVES AND INTERMEDIATES THEREOF [FR] UTILISATION DE PEPTIDES CYCLIQUES DE TYPE ANABAENOPEPTINE DESTINES AU TRAITEMENT D'UN ETAT POUR LEQUEL L'INHIBITION DE LA CARBOXYPEPTIDASE U EST BENEFIQUE, DERIVES DE L'ANABAENOPEPTINE ET INTERMEDIAIRES DE CELLE-CI
[EN] USE OF CYCLIC ANABAENOPEPTIN-TYPE PEPTIDES FOR THE TREATMENT OF A CONDITION WHEREIN INHIBITION OF CARBOXYPEPTIDASE U IS BENEFICIAL, NOVEL ANABAENOPEPTIN DERIVATIVES AND INTERMEDIATES THEREOF<br/>[FR] UTILISATION DE PEPTIDES CYCLIQUES DE TYPE ANABAENOPEPTINE DESTINES AU TRAITEMENT D'UN ETAT POUR LEQUEL L'INHIBITION DE LA CARBOXYPEPTIDASE U EST BENEFIQUE, DERIVES DE L'ANABAENOPEPTINE ET INTERMEDIAIRES DE CELLE-CI
申请人:ASTRAZENECA AB
公开号:WO2005039617A1
公开(公告)日:2005-05-06
The use of a compound of formula (I): in a method of manufacturing a medicament for the treatment or prophylaxis of a condition wherein inhibition of carboxypeptidase U is beneficial; specified compounds of formula (I) and compositions comprising a compound of formula (I) and a pharmaceutically acceptable adjuvant, diluent or carrier.